Evaluation of Array Comparative genomic Hybridisation in prenatal diagnosis of fetal anomalies: a multicentre cohort study with cost analysis and assessment of patient, health professional and commissioner preferences for array comparative genomic hybridisation

Stephen C Robson,1* Lyn S Chitty,2 Stephen Morris,3 Talitha Verhoeef,3 Gareth Ambler,4 Diana G Wellesley,5 Ruth Graham,6 Claire Leader,1 Jane Fisher7 and John A Crolla8

1Institute of Cellular Medicine, Newcastle University, Newcastle, UK
2Institute of Child Health, University College London, London, UK
3Department of Applied Health Research, University College London, London, UK
4Department of Statistical Science, University College London, London, UK
5Department of Genetics, Princess Anne Hospital, Southampton, UK
6School of Geography, Politics and Sociology, Newcastle University, Newcastle, UK
7Antenatal Results and Choices, London, UK
8Wessex Regional Genetics Laboratory, Salisbury, UK

*Corresponding author

Declared competing interests of authors: none

Disclaimer: This report contains transcripts of interviews conducted in the course of the research and contains language that may offend some readers.

Published February 2017
DOI: 10.3310/eme04010

Plain English summary

The EACH Study
Efficacy and Mechanism Evaluation 2017; Vol. 4: No. 1
DOI: 10.3310/eme04010

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

One of the main aims of ultrasound scans during pregnancy is to detect fetal abnormalities, some of which are due to imbalances (gains or losses) of part or all of a chromosome. Each cell in the body contains 23 pairs of chromosomes and one of each pair is inherited from each parent. The chromosomes carry a person’s genetic information stored as deoxyribonucleic acid. Babies with chromosomal imbalances have complex problems. Testing for chromosome imbalances involves tests (e.g. amniocentesis) that occasionally cause miscarriage. Major chromosome problems (e.g. Down syndrome) can be detected quickly by a polymerase chain reaction (PCR) test. Less common imbalances require the baby’s cells to be grown and examined; this test (karyotyping) detects only large chromosomal imbalances. Chromosomal microarray (CMA) is a new genetic test that detects smaller chromosomal imbalances. Interpreting CMA is complex as not all imbalances cause problems. The purpose of the Evaluation of Array Comparative genomic Hybridisation (EACH) study was to help the NHS decide whether or not CMA should replace karyotyping.

Over 1100 women with a fetal abnormality detected on ultrasound and without a major chromosomal problem (as indicated by a normal PCR test) participated in the EACH study. CMA detected 3–4% more significant chromosome imbalances than karyotyping when the reason for testing was a major abnormality in one of the baby’s organs, but not when there was increased fluid at the back of the baby’s neck (nuchal translucency). The time from setting up the test to reporting the result of the test was 5 days less with CMA than karyotyping. Although the cost of CMA (£322) was slightly more than karyotyping, the cost for each extra chromosome imbalance detected (which was thought to explain the abnormal scan) was £9418. Interviews suggested that parents and health professionals found the CMA test acceptable despite the uncertainties it may introduce. The results suggest that CMA should replace karyotyping for the detection of chromosome imbalances in abnormal fetuses.
Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)
ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nhredit@southampton.ac.uk

The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Efficacy and Mechanism Evaluation journal

Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting ‘science driven’ studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: http://www.nets.nihr.ac.uk/programmes/eme

This report

The research reported in this issue of the journal was funded by the EME programme as project number 10/60/03. The contractual start date was in February 2012. The final report began editorial review in August 2015 and was accepted for publication in September 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Robson et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
**Efficacy and Mechanism Evaluation Editor-in-Chief**

**Professor David Crossman**  Bute Professor of Medicine and Dean and Head of Faculty of Medicine, University of St Andrews, and Honorary Consultant Cardiologist, NHS Fife Health Board, UK

**NIHR Journals Library Editor-in-Chief**

**Professor Tom Walley**  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

**NIHR Journals Library Editors**

**Professor Ken Stein**  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andree Le May**  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key**  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck**  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen's University Belfast, UK

**Professor Aileen Clarke**  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin**  Senior Scientific Advisor, Wessex Institute, UK

**Ms Tara Lamont**  Scientific Advisor, NETSCC, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Professor of Health Sciences Research, Health and Wellbeing Research Group, University of Winchester, UK

**Professor John Norrie**  Chair in Medical Statistics, University of Edinburgh, UK

**Professor John Powell**  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood**  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:  
www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:** nihredit@southampton.ac.uk